	US 12,448,430 B2
	High avidity WT1 T cell receptors and uses thereof
Thomas M. Schmitt, Seattle, WA (US); Aude G. Chapuis, Seattle, WA (US); and Philip D. Greenberg, Mercer Island, WA (US)
Assigned to FRED HUTCHINSON CANCER CENTER, Seattle, WA (US)
Appl. No. 17/438,380
Filed by FRED HUTCHINSON CANCER CENTER, Seattle, WA (US)
PCT Filed Mar. 10, 2020, PCT No. PCT/US2020/021916 § 371(c)(1), (2) Date Sep. 10, 2021, PCT Pub. No. WO2020/185796, PCT Pub. Date Sep. 17, 2020.
Claims priority of provisional application 62/816,746, filed on Mar. 11, 2019.
Prior Publication US 2022/0160764 A1, May 26, 2022
Int. Cl. A61K 35/17 (2025.01); A61K 40/11 (2025.01); A61K 40/32 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01); A61K 38/00 (2006.01)

CPC C07K 14/7051 (2013.01) [A61K 40/11 (2025.01); A61K 40/32 (2025.01); A61K 40/4243 (2025.01); A61P 35/00 (2018.01); C12N 5/0636 (2013.01); A61K 38/00 (2013.01); A61K 2239/49 (2023.05); A61K 2239/54 (2023.05)]

49 Claims

1. A host cell comprising a heterologous polynucleotide encoding a T cell receptor (TCR), wherein the TCR comprises:

(a) a TCR α-chain variable (Vα) domain comprising the CDR1α amino acid sequence set forth in SEQ ID NO:194, the CDR2a amino acid sequence set forth in SEQ ID NO:195, and the CDR3a amino acid sequence set forth in SEQ ID NO:196 or 12; and

(b) a TCR β-chain variable (VB) domain comprising the CDR1β amino acid sequence set forth in SEQ ID NO:197, the CDR2β amino acid sequence set forth in SEQ ID NO:198, and the CDR3β amino acid sequence set forth in SEQ ID NO:199 or 1,

wherein the TCR binds to a VLDFAPPGA (SEQ ID NO:59): human leukocyte antigen (HLA) complex, wherein the HLA comprises HLA-A*201.